Welcome to our dedicated page for NextCure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on NextCure stock.
NextCure, Inc. (Nasdaq: NXTC) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel immunomedicines aimed at treating cancer and other immune-related diseases by restoring normal immune function. The company’s leading product candidate, NC318, is currently in Phase 2 clinical trials for advanced or metastatic solid tumors. NextCure is also advancing NC410, a novel immunomedicine designed to block immune suppression mediated by the immune modulator LAIR-1, and LNCB74, an ADC targeting B7-H4, a clinically validated cancer target. The company's pipeline includes additional antibodies in preclinical development targeting novel immune modulators expressed in inflamed tissue and tumor microenvironments across various cancer types.
NextCure has established significant partnerships including a license agreement with Yale University and a research collaboration with LigaChem Biosciences. Recent updates in their clinical pipeline include promising preclinical data on NC605 for preventing bone loss in patients with severe spinal cord injuries and the publication of a manuscript on the FLRT3-UNC5B pathway as a novel T cell checkpoint in cancer immunotherapy. Their innovative FIND-IO platform continues to discover new immunomedicine targets, expanding their therapeutic potential beyond oncology to chronic inflammatory diseases like COPD.
Financially, NextCure has a solid runway extending into the second half of 2026, focusing resources on high-priority programs such as NC410 in combination therapies and LNCB74, while seeking partners for other clinical and preclinical assets. The company's goal is to address unmet medical needs by providing new treatments for patients who do not respond to existing therapies or experience disease progression, leveraging scientific insights into biological pathways, cell interactions, and tumor microenvironments.
For the latest updates, visit www.nextcure.com
NextCure, a clinical-stage biopharmaceutical company, reported its first-quarter 2024 financial results and provided a business update. They highlighted presenting Phase 1b data for NC410 combo with pembro at the ASCO Annual Meeting, showcasing preclinical data from LNCB74 at the AACR Annual Meeting, and having cash of approximately $96.0 million to fund operations into the second half of 2026. The company is focused on developing novel cancer therapies.
FAQ
What is the current stock price of NextCure (NXTC)?
What is the market cap of NextCure (NXTC)?
What is NextCure, Inc. known for?
What are the key products in development at NextCure?
What partnerships does NextCure have?
What is NC318?
How does NC410 work?
What recent achievements has NextCure made?
What is the FIND-IO platform?
What is LNCB74?
What is NextCure’s financial outlook?
Where can I find the latest updates on NextCure?
